Courts have not always been able to appreciate the complexities around antibody patents, causing problems for innovation and investment, says Eli Lilly patent counsel Duane Marks in an interview with LSIPR.
The IP team at AstraZeneca must “ruthlessly” prioritise how it spends time and resources, its vice president of global IP explained in an interview.
The financial stakes in the biosimilars market are enormous, and an understanding of sequence IP for the underlying technologies and modes of action is key to entry into it, say Henk Heus and Ellen Sherin of GQ Life Sciences.
Forming licensing agreements with other pharmaceutical companies is an important part of Pieris’s strategy, according to Ahmed Mousa, vice president of licensing, IP and legal affairs at the clinical-stage company.
Politics has a huge impact on enforcement in Africa, Asia and the Middle East, a senior corporate counsel at Pfizer has told LSIPR in an interview.
While the impact of the European Medicines Agency’s relocation from London to Amsterdam is unknown, industry and government will try to ensure that the UK remains at the forefront of medicines regulation, says Rachel Bradley of Penningtons Manches.
Major tasks for Carl Gordon of OrbiMed, a healthcare fund, include drug pricing and helping to turn promising ideas into reality, as he tells LSIPR.
Thomas Kirkbak, chief IP litigation specialist at Danish company Lundbeck, faces challenges on several fronts, as he explains to LSIPR.
In the current IP landscape it is wise to be prepared for attacks on important patents, as Lars Kellberg, corporate vice president and corporate patents of Novo Nordisk, explains to LSIPR.
Pharmaceutical company UCB injects a significant amount of revenue into R&D, but it is mindful of the risks attached to drug investment. Global head of IP Stéphane Drouin explains more in an interview with LSIPR.